by Rod Raynovich | Apr 15, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL) added as speculative buy at $3.30 on 9/2/10 Update: Portfolio rebalancing below but we are still in a bearish mode with small cap biotech. The brief rally spurred by a potential buyout rumor by Sanofi last Friday has evaporated with Biogen,Celgene...
by Rod Raynovich | Apr 5, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Quidel (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27. Celera(CRA) is...
by Rod Raynovich | Apr 1, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross...
by Rod Raynovich | Mar 23, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The Raygent Model Portfolio was created in February 2009 and will be updated by the end of March 2010.The 14 month YTD performance is up 25%. New buys over past four months were Sequenom (SQNM) and SeraCare (SRLS). Currently under review are Immucor (BLUD) ,...
